Daewon Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Daewon Pharmaceutical has been growing earnings at an average annual rate of 3.5%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 14.6% per year. Daewon Pharmaceutical's return on equity is 4.5%, and it has net margins of 2.6%.
Key information
3.5%
Earnings growth rate
4.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 14.6% |
| Return on equity | 4.5% |
| Net Margin | 2.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31
Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Revenue & Expenses Breakdown
How Daewon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 566,094 | 14,688 | 227,054 | 11,410 |
| 31 Mar 24 | 561,164 | 23,534 | 219,734 | 9,963 |
| 31 Dec 23 | 526,952 | 23,917 | 207,935 | 9,010 |
| 30 Sep 23 | 508,634 | 26,133 | 196,990 | 12,621 |
| 30 Jun 23 | 501,899 | 31,749 | 190,020 | 12,849 |
| 31 Mar 23 | 485,917 | 31,071 | 182,703 | 12,406 |
| 31 Dec 22 | 478,885 | 31,944 | 174,709 | 12,646 |
| 30 Sep 22 | 457,308 | 34,728 | 164,955 | 4,445 |
| 30 Jun 22 | 425,588 | 29,928 | 157,674 | 2,844 |
| 31 Mar 22 | 396,239 | 25,575 | 151,307 | 1,992 |
| 31 Dec 21 | 354,176 | 6,989 | 144,457 | 0 |
| 30 Sep 21 | 330,686 | 3,431 | 146,807 | -882 |
| 30 Jun 21 | 315,870 | 657 | 143,776 | 101 |
| 31 Mar 21 | 302,889 | 2,120 | 136,538 | -736 |
| 31 Dec 20 | 308,501 | 17,640 | 135,470 | 0 |
| 30 Sep 20 | 318,297 | 24,073 | 123,369 | 11,871 |
| 30 Jun 20 | 318,091 | 27,037 | 125,524 | 9,224 |
| 31 Mar 20 | 322,124 | 28,904 | 128,199 | 10,014 |
| 31 Dec 19 | 317,828 | 27,289 | 128,731 | 10,244 |
| 30 Sep 19 | 310,802 | 25,085 | 126,538 | 10,315 |
| 30 Jun 19 | 299,871 | 23,773 | 122,658 | 10,967 |
| 31 Mar 19 | 291,785 | 22,795 | 121,070 | 11,003 |
| 31 Dec 18 | 286,653 | 23,744 | 120,679 | 9,275 |
| 30 Sep 18 | 279,338 | 18,195 | 120,818 | 8,563 |
| 30 Jun 18 | 279,933 | 21,779 | 120,753 | 8,205 |
| 31 Mar 18 | 273,784 | 14,212 | 118,951 | 6,737 |
| 31 Dec 17 | 265,462 | 10,742 | 115,507 | 6,762 |
| 30 Sep 17 | 258,275 | 14,662 | 109,595 | 6,511 |
| 30 Jun 17 | 248,350 | 13,180 | 104,415 | 6,143 |
| 31 Mar 17 | 245,490 | 19,632 | 101,108 | 6,285 |
| 31 Dec 16 | 240,722 | 20,242 | 97,063 | 6,634 |
| 30 Sep 16 | 235,046 | 20,787 | 94,468 | 5,060 |
| 30 Jun 16 | 229,691 | 16,712 | 92,206 | 5,826 |
| 31 Mar 16 | 222,267 | 17,791 | 87,827 | 5,650 |
| 31 Dec 15 | 216,187 | 17,695 | 84,090 | 6,436 |
| 30 Sep 15 | 208,270 | 17,453 | 77,621 | 9,789 |
| 30 Jun 15 | 201,669 | 19,596 | 72,817 | 10,929 |
| 31 Mar 15 | 190,870 | 17,286 | 70,645 | 10,689 |
| 31 Dec 14 | 181,985 | 15,729 | 68,963 | 10,038 |
| 30 Sep 14 | 174,309 | 14,143 | 66,514 | 8,238 |
| 30 Jun 14 | 168,940 | 11,977 | 65,987 | 6,549 |
| 31 Mar 14 | 165,717 | 12,625 | 62,439 | 6,250 |
| 31 Dec 13 | 158,879 | 12,321 | 60,470 | 5,754 |
| 30 Sep 13 | 152,578 | 12,210 | 57,349 | 5,588 |
Quality Earnings: A003220 has a large one-off loss of ₩6.3B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: A003220's current net profit margins (2.6%) are lower than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A003220's earnings have grown by 3.5% per year over the past 5 years.
Accelerating Growth: A003220's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A003220 had negative earnings growth (-53.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.6%).
Return on Equity
High ROE: A003220's Return on Equity (4.5%) is considered low.